Evidence map›Paper›PMID 34315481›Full record

ArticleCardiovascular diabetology2021

CAPTURE: a multinational, cross-sectional study of cardiovascular disease prevalence in adults with type 2 diabetes across 13 countries.

Ofri Mosenzon, Abdullah Alguwaihes, Jose Luis Arenas Leon, Fahri Bayram, Patrice Darmon, Timothy M E Davis, Guillermo Dieuzeide, Kirsten T Eriksen, Tianpei Hong, Margit S Kaltoft and 7 more

2 registry-linked trialsAbstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Cardiovascular diabetology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 143 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
143citing papers in PubMed, 5 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03786406 completednot on this map

A Non-interventional Cross-sectional Study to Capture the Prevalence of Cardiovascular Disease in Patients With Type 2 Diabetes in Selected Countries in Europe

TypeobservationalSponsorNovo Nordisk A/SRan2018 to 2019Enrolled2,275ConditionsDiabetes Mellitus, Type 2ArmsNo treatment given
NCT03811288 completednot on this map

A Non-interventional Cross-sectional Study to Capture the Prevalence of Cardiovascular Disease in Patients With Type 2 Diabetes - an International Observation

TypeobservationalSponsorNovo Nordisk A/SRan2018 to 2019Enrolled7,548ConditionsDiabetes Mellitus, Type 2ArmsNo treatment given
3 · Its place in the literature

Who cites it

143 citing papers in PubMed, 5 syntheses or guidelines pooled it.

  1. Pooled it
  2. Effect ofInternational journal of molecular sciences · 2024
    Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Trial
  7. Trial
  8. Review
  9. Review
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Modern Management of CKM Syndrome: Use of GLP-1 Receptor Agonists in a Multidisciplinary Setting-Expert Group Recommendations from Kuwait.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2026
    Review
  17. Article
  18. Article
  19. Review
  20. Article

83 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Ofri MosenzonDiabetes Unit, Department of Endocrinology and Metabolism, Hadassah Medical Center, Faculty of Medicine, Hebrew University of Jerusalem, Hadassah Hebrew University Hospital, PO Box 12000, 91120, Jerusalem, Israel. ofrim@hadassah.org.il.ORCID 0000-0002-5702-7584
Abdullah AlguwaihesKing Saud University, King Saud University Medical City, Riyadh, Kingdom of Saudi Arabia.
Jose Luis Arenas LeonCentro de Atención E Investigación Cardiovascular del Potosí, San Luis Potosí, Mexico.
Fahri BayramDepartment of Endocrinology and Metabolism, Faculty of Medicine, Erciyes University, Kayseri, Turkey.
Patrice DarmonAix Marseille University, INSERM, INRA, C2VN, Marseille, France.
Timothy M E DavisMedical School, University of Western Australia, Fremantle Hospital, Fremantle, Australia.
Guillermo DieuzeideCentro de Atención Integral en Diabetes, Endocrinología Y Metabolismo, Chacabuco, Buenos Aires, Argentina.
Kirsten T EriksenNovo Nordisk A/S, Søborg, Denmark.
Tianpei HongDepartment of Endocrinology and Metabolism, Peking University Third Hospital, Beijing, China.
Margit S KaltoftNovo Nordisk A/S, Søborg, Denmark.
Csaba LengyelUniversity of Szeged, Szeged, Hungary.
Nicolai A RheeNovo Nordisk Health Care AG, Zurich, Switzerland.
Giuseppina T RussoDepartment of Clinical and Experimental Medicine, Policlinico Universitario, University of Messina, Messina, Italy.
Shinichiro ShirabeH. E. C Science Clinic, Yokohama, Japan.
Katerina UrbancovaDiabetologická Interní Ambulance S.R.O., Ostrava, Czech Republic.
Sergio VencioInstituto de Ciencias Farmaceuticas, Goiânia, Goiás, Brazil.
CAPTURE Study Investigators

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThere is a paucity of global data on cardiovascular disease (CVD) prevalence in people with type 2 diabetes (T2D). The primary objective of the CAPTURE study was to estimate the prevalence of established CVD and its management in adults with T2D across 13 countries from five continents. Additional objectives were to further characterize the study sample regarding demographics, clinical parameters and medication usage, with particular reference to blood glucose-lowering agents (GLAs: glucagon-like peptide-1 receptor agonists and sodium-glucose co-transporter-2 inhibitors) with demonstrated cardiovascular benefit in randomized intervention trials.

methodsData were collected from adults with T2D managed in primary or specialist care in Australia, China, Japan, Czech Republic, France, Hungary, Italy, Argentina, Brazil, Mexico, Israel, Kingdom of Saudi Arabia, and Turkey in 2019, using standardized methodology. CVD prevalence, weighted by diabetes prevalence in each country, was estimated for the overall CAPTURE sample and participating countries. Country-specific odds ratios for CVD prevalence were further adjusted for relevant demographic and clinical parameters.

resultsThe overall CAPTURE sample included 9823 adults with T2D (n = 4502 from primary care; n = 5321 from specialist care). The overall CAPTURE sample had median (interquartile range) diabetes duration 10.7 years (5.6-17.9 years) and glycated hemoglobin 7.3% (6.6-8.4%) [56 mmol/mol (49-68 mmol/mol)]. Overall weighted CVD and atherosclerotic CVD prevalence estimates were 34.8% (95% confidence interval [CI] 32.7-36.8) and 31.8% (95% CI 29.7-33.8%), respectively. Age, gender, and clinical parameters accounted for some of the between-country variation in CVD prevalence. GLAs with demonstrated cardiovascular benefit were used by 21.9% of participants, which was similar in participants with and without CVD: 21.5% and 22.2%, respectively.

conclusionsIn 2019, approximately one in three adults with T2D in CAPTURE had diagnosed CVD. The low use of GLAs with demonstrated cardiovascular benefit even in participants with established CVD suggested that most were not managed according to contemporary diabetes and cardiology guidelines. Study registration NCT03786406 (registered on December 20, 2018), NCT03811288 (registered on January 18, 2019).

Indexed as

AgedCardiovascular DiseasesCross-Sectional StudiesDiabetes Mellitus, Type 2FemaleHumansHypoglycemic AgentsMaleMiddle AgedPrevalencePrognosisProtective FactorsRisk AssessmentRisk FactorsTime FactorsHypoglycemic AgentsAtherosclerotic cardiovascular diseaseCardiovascular diseaseGlucagon-like peptide-1 receptor agonistsNon-interventional studyPrevalenceSodium-glucose co-transporter-2 inhibitorsType 2 diabetes

Identifiers

PMID34315481
PMCPMC8317423

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.